Vivantes hospital in Berlin chooses SensoDetect Technology to measure impact of Dialysis on patients with kidney disease
The population of ESRD (end stage renal disease) patients on dialysis are approximately 2.2 million patients, growing at a steady rate of 4-6% per year. ESRD poses a large cost to society and health care as each patient are treated approx. three times per week for 4 hours (150 times per year).
One of the main challenges for patients with kidney disease is the impact dialysis has on the brain (structural brain abnormalities and cognitive impairment). This can lead to the patient not attending treatments or mismanaging their medications, which has a profound impact on the patient and can ultimately lead to mortality.
To this date it is not clear what in dialysis causes this changes in the patient’s brain. For this reason, Prof. Dr. Kuhlmann at Vivantes hospital in Berlin, is launching a study to learn more about how different parts of the brainstem may be affected during dialysis (hemodialysis or peritoneal dialysis). Such knowledge might allow to develop measures to treat and adjust the dialysis therapy in relation to this risk.
In order to do the measurements of the brain Prof. Dr. Kuhlmann and SensoDetect have signed a cooperation agreement.
Prof. Dr. Kuhlmann “This is one of the big challenges in renal care today. SensoDetects BERA technology is a very important tool for us in investigating the reason for the changes in the patient’s brain during dialysis and finding a solution to the problem.”
The study will be a three step approach.
Step 1) A feasibility test of the BERA tool will be done on-site at the dialysis unit of Vivantes Klinikum im Friedrichshain. When confirmed that ABR can be assessed by BERA undisturbed by a dialysis environment the study will continue.
Step 2) A clinical study in approx. 20 dialysis patients with ESRD (end stage renal disease) using SensoDetect’s Auditory Brainstem Response (ABR) measurement system.
3) Depending on the results of the Step-2 study a larger prospective study in a bigger group of patients over a longer period time using SensoDetect’s Auditory Brainstem Response (ABR) measurement system.
“This is a very interesting project where yet again our technology is very relevant when trying to improve the lives of patients. This can potentially improve the lives of many patients with kidney disease.”, says CEO Johan Olson, Sensodetect AB (publ.)
Johan Olson
VD, SensoDetect Aktiebolag (publ)
Tel: +46 46 151 273
e-mail: jo@sensodetect.com
Prof. Dr. Martin K. Kuhlmann
Nephrologe, Diabetologe, Hypertensiologe
Ärztlicher Direktor
Chefarzt Innere Medizin – Nephrologie
Vivantes Klinikum im Friedrichshain
Tel.: +49 30 13023 1322
The information in this press release is as SensoDetect AB is required to publish under the EU Market Abuse Regulation. The information was provided, through the contact person of the abovementioned person, for publication on 29 June 2017.
SensoDetect highlights through patented equipment brain stem responses to audio stimuli in order to provide health care clear anomalies and patterns for use primarily within psychiatry. The goal is to increase efficiency in Psychiatry and thus the benefits for health care, society, patients and relatives.
Tags: